The Mesoblast Ltd (ASX: MSB) share price is in focus today after the company reported net revenues of US$30.3 million from its flagship Ryoncil® product in the March quarter and improved its net operating cash spend to just US$4.1 million.
Image source: Getty Images
What did Mesoblast report?
- Ryoncil® gross sales: US$35.3 million for the quarter, with net revenues of US$30.3 million
- Net operating cash spend: US$4.1 million for the quarter
- Total cash at quarter end: US$122 million
- Receipts from customers: US$34.6 million
- Total Ryoncil® revenue since launch approaches US$100 million
- Patient recruitment target achieved for pivotal phase 3 trial of rexlemestrocel-L in chronic low back pain
What else do investors need to know?
Mesoblast achieved a key milestone by hitting its patient recruitment goal in a pivotal phase 3 trial for chronic low back pain, marking progress on its next-generation product pipeline. The company also obtained US FDA clearance for registrational trials of Ryoncil® in new indications, including Duchenne's muscular dystrophy and adult steroid-refractory acute graft versus host disease (SR-aGvHD).
During its inaugural R&D day, Mesoblast announced the acquisition of a patented chimeric antigen receptor (CAR) technology, aiming to bolster its cell therapy portfolio, especially in autoimmune diseases like lupus nephritis and inflammatory bowel conditions. The company noted a strong cash position and prudent expense management, supporting its ongoing research and commercial activities.
What did Mesoblast management say?
Mesoblast Chief Executive Dr. Silviu Itescu said:
We've had a busy and exciting March quarter marked by a series of major achievements. Ryoncil® revenues are now approaching US$100 million since last year's launch, we have substantially improved our net operating cash spend, our pivotal trial in inflammatory back pain has successfully achieved its patient recruitment target, and we have bolstered our long-term leadership in the field by acquiring genetically modified technology for precision-enhanced cell therapy products.
What's next for Mesoblast?
Mesoblast plans to keep expanding Ryoncil® use into more indications, with new clinical trials for adults and rare paediatric diseases now cleared to proceed in the United States. The next phase of the company's strategy centres on advancing its CAR technology and next-generation MSC therapies into new auto-immune conditions and growing international commercial opportunities.
With over US$120 million in cash and ample funding facilities, management says the company is well-positioned to invest in research, regulatory approvals, and further market launches in 2026 and beyond.
Mesoblast share price snapshot
Over the past 12 months, Mesoblast shares have risen 19%, outperforming the S&P/ASX 200 Index (ASX: XJO) which has risen 6% over the same period.
